When Will the U.S. Flinch at Cancer Drug Prices?
Open Access
- 4 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 97 (9) , 624-626
- https://doi.org/10.1093/jnci/97.9.624
Abstract
High hopes in cancer research are pinned on the targeted therapies—those that aim directly at cancer cells or that cut off a tumor's blood supply without harming healthy tissue. And 2004 was a banner year for such drugs reaching the marketplace; Avastin (bevacizumab), Erbitux (cetuximab), Tarceva (erlotinib), and Iressa (gefitinib) all became available to great fanfare.Keywords
This publication has 0 references indexed in Scilit: